Two new subtypes of MASH revealed with different risks and outcomes Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z × Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member Two new subtypes of MASH revealed with different risks and outcomes Download PDF Copy Reviewed INSERM (Institut national de la santé et de la recherche médicale) Dec 9 2024 Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease spans from benign fat accumulation in the liver (steatosis) to its more severe form, metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH). MASH represents a dangerous progression, with the potential to cause cirrhosis, liver cancer, type 2 diabetes, and cardiovascular disease. Despite its prevalence, MASH remains highly heterogeneous. Not all individuals follow the same clinical trajectory, and conventional treatment approaches often fail to account for these differences. Recognizing this gap, a groundbreaking study led by Prof. François Pattou and Prof. Stefano Romeo has redefined MASH by identifying two distinct subtypes with distinct risks and outcomes. This transformative research, conducted at Lille University Hospital as part of the RHU PreciNASH project coordinated by Inserm, was made possible through collaboration with leading scientific teams from Inria, CNRS, the University of Lille, Lille University Hospital, and the Pasteur Institute of Lille, alongside international partners from Sweden, Italy, Belgium, and Finland. Published in Nature Medicine , the study marks a pivotal shift in the understanding and treatment of MASH. Two subtypes of MASH, two distinct risk profiles The study identified and validated two distinct types of MASH based on histology and liver imaging, using data from European cohorts and the UK Biobank : Liver-Specific MASH: A genetically driven subtype with rapid progression of liver disease but a surprisingly low risk of cardiovascular complications. Cardiometabolic MASH: A high-risk profile linked to type 2 diabetes and cardiovascular diseases, alongside comparable liver disease progression. What makes this discovery groundbreaking is that both subtypes exhibit similar histological features under the microscope or on imaging, making them indistinguishable using traditional diagnostic methods. However, their markedly different clinical outcomes underscore the critical need for advanced diagnostic tools and personalized interventions. Transforming diagnosis and treatment This study empowers clinicians to move beyond one-size-fits-all approaches to treating MASH. By leveraging simple clinical markers - age, BMI, HbA1c, LDL cholesterol, triglycerides, and ALT - patients can be stratified into specific subtypes, enabling tailored treatments: Liver-Specific MASH : Focus on therapies to halt liver damage and prevent progression to cirrhosis or liver cancer. Cardiometabolic MASH : Emphasize aggressive management of metabolic and cardiovascular risks alongside liver disease treatment. " This research marks a turning point ," says Prof. François Pattou. " We now have a clear path to develop subtype-specific treatments that can improve patient outcomes ." Why this discovery matters MASH is the most severe manifestation of MASLD, with the potential for devastating health consequences. However, its heterogeneity has often been overlooked, leading to inconsistent treatment outcomes. Related Stories MET signaling plays a critical protective role in acetaminophen-induced acute liver failure Researchers develop new score to predict the risk of liver cancer A dual-action approach to preventing hepatocellular carcinoma " This manuscript offers a transformative perspective on MASH and its heterogeneous outcomes ," notes an anonymous reviewer. " Thoughtfully conducted on large, well-characterized cohorts, it opens new doors for precision medicine in this field. " The science behind the subtypes The study utilized data from the French ABOS cohort of 1,389 individuals with obesity and validated its findings across three European MASLD cohorts (Italy, Belgium, and Finland), comprising 1,099 participants, as well as imaging data (MRI) from over 6,000 UK Biobank participants. By integrating clinical traits with liver transcriptomics and plasma metabolomics, researchers uncovered distinct biological pathways driving each subtype. " This discovery sheds light on why current treatments often yield inconsistent results ," explains co-lead researcher Prof. Stefano Romeo. " It was a true 'eureka' moment for our team ." A new era for MASH treatment This breakthrough highlights the urgent need for subtype-specific care, paving the way for innovative treatments and personalized medicine. Future research will explore how these subtypes respond to lifestyle interventions, pharmacological therapies, and other treatments in diverse populations. " We've always known MASH was heterogeneous ," concludes Prof. Romeo. " Now, we finally have a roadmap to turn these insights into real-world solutions for patients. " Source: INSERM (Institut national de la santé et de la recherche médicale) Journal reference: Raverdy, V., et al . (2024). Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nature Medicine . doi.org/10.1038/s41591-024-03283-1 . Posted in: Medical Research News | Medical Condition News Comments (0) Download PDF Copy Suggested Reading Myosteatosis: An emerging predictor of outcomes in chronic liver disease Bacterial infections in patients with liver cirrhosis show rising prevalence and high mortality Do cocoa flavanols influence heart and fatty liver risk factors? Cornell study finds existing drug could boost liver cancer immunotherapy Liver-derived protein supports bone health in males Engineered liver tissue model mimics early metabolic liver disease Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma Study explores whether a bidirectional causal link exists between MASLD and sarcopenia Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post Sign in to keep reading We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free. Sign in with Google Sign in with Apple Sign in with LinkedIn Sign in with Facebook or Sign in with email Trending Stories Latest Interviews Top Health Articles Case report examines potential cancer risks after mRNA vaccination Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Researchers identify a previously unknown cellular barrier in the brain Ozempic users continue treatment when weight loss works despite side effects Advancing brain microphysiological systems (bMPS) Dr. Lena Smirnova Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. PhD researcher at LifeArc Natasha Bury Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research Rosanna Zhang In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as Food: Nutritional Benefits, Safety, and Environmental Impact Latest News Researchers discover a way to breach cancer’s impenetrable fortress Weekend holiday rehabilitation supports recovery in elderly hip fracture patients Novel implant delivers tiny growth-promoting particles directly to injured nerve cells Changes in lymphatic vessels can help identify aggressive oral cancer at an early stage Axol Bioscience acquires ophthalmology business from Newcells Biotech Newsletters you may be interested in Diabetes ( Subscribe or Preview ) Cholesterol ( Subscribe or Preview ) Digital Pathology & Histology ( Subscribe or Preview ) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home Functional Food News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Posters Podcasts Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Posters Podcasts Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions . Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Wednesday 18 Feb 2026 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2026 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content . Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI . Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy . Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms . Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × SynGenSys introduces Liver.SET synthetic promoter library for liver-specific gene expression for in vivo gene therapies

Two subtypes of MASH, two distinct risk profiles The study identified and validated two distinct types of MASH based on histology and liver imaging, using data from European cohorts and the UK Biobank : Liver-Specific MASH: A genetically driven subtype with rapid progression of liver disease but a surprisingly low risk

… and Finland. Published in Nature Medicine , the study marks a pivotal shift in the understanding and treatment of MASH. Two subtypes of MASH, two distinct risk profiles The study identified and validated two distinct types of MASH based on histology and liver imaging, using data from European cohorts and the UK Biobank : Liver-Specific MASH: A genetically driven subtype with rapid progression of liver disease but a surprisingly low ris k of cardiovascular complications. Cardiometabolic MASH: A high-risk profile linked to type 2 diabetes and cardiovascula…

By leveraging simple clinical markers - age, BMI, HbA1c, LDL cholesterol, triglycerides, and ALT - patients can be stratified into specific subtypes, enabling tailored treatments: Liver-Specific MASH : Focus on therapies to halt liver damage and prevent progression to cirrhosis or liver cancer.

…ing diagnosis and treatment This study empowers clinicians to move beyond one-size-fits-all approaches to treating MASH. By leveraging simple clinical markers - age, BMI, HbA1c, LDL cholesterol, triglycerides, and ALT - patients can be stratified into specific subtypes, enabling tailored treatments: Liver-Specific MASH : Focus on therapies to halt liver damage and prevent progression to cirrhosis or liver cancer . Cardiometabolic MASH : Emphasize aggressive management of metabolic and cardiovascular risks alongside liver disease t…

" A new era for MASH treatment This breakthrough highlights the urgent need for subtype-specific care, paving the way for innovative treatments and personalized medicine.

… inconsistent results ," explains co-lead researcher Prof. Stefano Romeo. " It was a true 'eureka' moment for our team . " A new era for MASH treatment This breakthrough highlights the urgent need for subtype-specific care, paving the way for innovative treatments and personalized medicine. Future research will explore how these subtypes respond to lifestyle interventions, pharmacological therapies, and othe…